Advances in Treatment of Cholestatic Liver Diseases
10.3969/j.issn.1008-7125.2020.04.010
- VernacularTitle: 胆汁淤积性肝病治疗方法的新进展
- Author:
Yuecheng GUO
1
Author Information
1. Department of Gastroenterology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Publication Type:Journal Article
- Keywords:
Cholangitis, Sclerosing;
Cholestatic Liver Diseases;
Liver Cirrhosis, Biliary;
Therapy
- From:Chinese Journal of Gastroenterology
2020;25(4):238-241
- CountryChina
- Language:Chinese
-
Abstract:
Cholestatic liver diseases (CLD) are a series of hepatobiliary diseases characterized by dysfunction of bile formation, secretion and excretion and are induced by immune, genetic and environmental factors. The development and pathogenesis of CLD is still unclear, and it has a risk of progression to liver fibrosis and cirrhosis. Traditional medicines such as ursodeoxycholic acid (UDCA), glucocorticoids and immunosuppressants have certain limitations. More and more studies provide new insights into the mechanism of cholestasis to explore the therapeutic targets, and various drugs such as all-trans retinoic acid, microecologics and norursodeoxycholic acid emerge as new therapeutic drugs. This article reviewed the advances in treatment of CLD.
